Skip to main content
Fig. 8 | BMC Cancer

Fig. 8

From: The real-world safety profile of pemetrexed and platinum with or without pembrolizumab: insights from a comparative analysis of FAERS database

Fig. 8

Comparison of the cumulative incidence of adverse events related to combination therapy (pembrolizumab + pemetrexed + platinum) and chemotherapy alone (pemetrexed + platinum). (A) All adverse events (AEs). (B) blood and lymphatic system disorders. (C) respiratory, thoracic and mediastinal disorders. (D) renal and urinary disorders. Abbreviations: PPP, pemetrexed and platinum with pembrolizumab; PP, pemetrexed and platinum

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us